SeerPharma Sponsoring & Exhibiting @ Biologics Manufacturing Asia 2018

The biologics manufacturing industry has undergone several changes over the past few years starting from the development of better expression systems to modular and flexible manufacturing facilities including the emergence and use of disposables. However, there is a need for higher productivity with upstream process development and cost-effective and alternative techniques when it comes to downstream processing. In addition, the industry also handles specific issues around designing facilities for flexibility with a common desire to manufacture multiple products.

The biologics industry in Asia- Pacific is estimated to be the fastest growing market in the world. The Asia- Pacific region alone accounts for 30% of the global biosimilar market.

The key drivers driving the growth of the biologics industry in Asia are new- cell culture techniques, fast-track GMP facilities, flexible manufacturing facilities using disposables, attempts for continuous manufacturing, combining modular facilities and single-use and other advances in the downstream processing of biologics. However, the factors hindering the growth of the biopharmaceutical industry mainly are driven by issues such as high-manufacturing complexities, expensive purification processes and other challenges across the bioprocessing value chain.

The 5th Annual Biologics Manufacturing Asia 2018 aims to provide a neutral platform to address the challenges faced in this sector including:

• Reducing timelines in upstream processing, such as reducing time for cell-line development.
• Need for efficient screening technologies and monitoring bioprocesses in order to reduce timelines for upstream bioprocesses.
• Incorporating Quality by Design (QbD) in early process development.
• Technical and economic viability of using a single-use biomanufacturing facility.
• Development of robust processes to suit evolving biomanufacturing needs.
• Purification process development to maximize process economy.
• Challenges in the downstream purification for highly complex molecules.
• Designing and automating quality control challenges during scale-up and process change.
• Observations in the use of disposables vs hard-piped steel containers.
• Perceived barriers to switch over from Batch to continuous manufacturing.
• Future of continuous manufacturing and the challenges faced by companies planning for the paradigm shift.

SeerPharma are proud to be sponsoring and exhibiting at this marquee event, and look forward to assisting delegates with these challenges, and their implications from a Quality Assurance and GMP compliance perspective. Join us in Singapore from the 30th January – 1^st  February 2018!

Visit the following website for more details:

http://www.imapac.com/business_conference/biomanufacturing-world-asia-2018/home/